Abstract Library

#4312 Developing innovative, genetically modified, proliferation-regulated patient-derived models representing human well-differentiated GEP-NETs for drug screening

Introduction: The slow-growing nature of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) has limited the development of clinically relevant models, hindering the discovery in the field.

Conference:

Presenting Author: Zuo X

Authors: Zuo X, Liu Y, Maxwell J, Halperin D, Dasari A,

Keywords: Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumour, Patient-Derived Cancer Model, Doxycycline-Controlled Genetic Modification, Drug Screening,

#3955 Development of clinically representative patient-derived organoid models for diverse G1/G2 gastroenteropancreatic neuroendocrine tumors

Introduction: While gastroenteropancreatic neuroendocrine tumors (GEP-NETs) grow slowly, they are incurable when reaching advanced stages. The characteristic slow growth of GEP-NETs results in the scarcity of clinically relevant models that has hindered our comprehension of GEP-NET biology and pathology, leading to limited progress in systemic therapies of GEP-NET treatment.

Conference:

Presenting Author:

Authors: Zuo X, Liu Y, Maxwelll J, Halperin D, Dasari A,

Keywords: gastroenteropancreatic neuroendocrine tumors, patient-derived organoids, Dox-controlled genetic modifications, characterization,